- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01819779
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
August 1, 2018 updated by: Hanlim Pharm. Co., Ltd.
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects
To assess the pharmacokinetic characteristics of valsartan and S-amlodipine after single oral administration of Exforge tab.
10/160mg, a combination formulation of valsartan and amlodipine as reference drug and Lodivixx tab
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to assess the pharmacokinetic characteristics of valsartan and S-amlodipine after single oral administration of Exforge tab.
10/160mg, a combination formulation of valsartan and amlodipine as reference drug and Lodivixx tab.
5/160mg, a combination formulation of valsartan and S-amlodipine as test drug in healthy male adults.
Additionally the safety and tolerability of two drugs will be evaluated.
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kyung Gi
-
Anyang, Kyung Gi, Korea, Republic of, 430-720
- Metro Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Years 20-45
- Body weight ≥ 50kg and 18 ≤ BMI ≤ 29kg/m2
- volunteer
Exclusion Criteria:
- Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
- Subject with symptoms of acute disease within 28days prior to study medication dosing
- Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug
- Subject with clinically significant active chronic disease
- Subject with any of the following conditions in laboratory test i. AST(sGOT) or ALT(sGPT) > Upper normal limit × 1.5 ii. Total bilirubin > Upper normal limit × 1.5 iii. renal failure with Creatinine clearance < 50mL/min
- Clinically significant hypotension when screening period (SBP < 100mmHg, DBP < 60mmHg)
- Positive test results for HBs Ab, HCV Ab, Syphilis regain test
- Use of any prescription medication within 14 days prior to study medication dosing
- Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
- Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)
- Subject with known for hypersensitivity reaction to S-amlodipine, amlodipine and valsartan and dihydropyridine derivatives
- Subject who is not able to taking the institutional standard meal
- Subjects with whole blood donation within 60days, component blood donation within 20days
- Subjects receiving blood transfusion within 30days prior to study medication dosing
- Participation in any clinical investigation within 60days prior to study medication dosing
- Continued excessive use of caffeine (caffeine > five cups/day), alcohol(alcohol>30g/day) and severe heavy smoker (cigarette > 10 cigarettes per day)
- Subject who has been taken meal which affect on the absorption, distribution, metabolism, excretion of drug, especially grapefruit juice
- Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 28days prior to study medication dosing
- Continued serum potassium concentration abnormal status (on baseline visit, < 3.5mEq/L or > 5.5mEq/L)
- Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator
- Severe renal insufficient subjects (creatinine clearance : less than 10mL/min)
- Severe hepatic insufficient subjects,billiary cirrhosis, biliary obstruction and cholestasis patient
- Combination with aliskiren in Diabetic patient or moderate to severe renal insufficient subjects (glomerular filtration rate<60mL/min/1.73m2)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Exforge tab. 10/160mg
|
Other Names:
|
Experimental: Lodivixx tab. 5/160mg
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum concentration)
Time Frame: Valsartan : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48hr (15 points), S-amlodipine : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 120, 168hr (18 points)
|
Valsartan : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48hr (15 points), S-amlodipine : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 120, 168hr (18 points)
|
AUC(area under curve)
Time Frame: Valsartan : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48hr (15 points), S-amlodipine : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 120, 168hr (18 points)
|
Valsartan : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48hr (15 points), S-amlodipine : 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 120, 168hr (18 points)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days and follow-up period for maximum 6 days from the discharge
|
Participants will be followed for the duration of hospital stay, an expected average of 3 days and follow-up period for maximum 6 days from the discharge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: KyoungSook Kim, PhD, Metro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2013
Primary Completion (Actual)
May 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
March 25, 2013
First Submitted That Met QC Criteria
March 27, 2013
First Posted (Estimate)
March 28, 2013
Study Record Updates
Last Update Posted (Actual)
August 3, 2018
Last Update Submitted That Met QC Criteria
August 1, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Valsartan
- Amlodipine, Valsartan Drug Combination
Other Study ID Numbers
- HL-LDV-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Subjects
-
AkesoNot yet recruitingHealthy Male Subjects
-
Sunshine Lake Pharma Co., Ltd.Completed
-
RAPT Therapeutics, Inc.Completed
-
AstraZenecaParexelCompletedHealthy Male SubjectsUnited States
-
AstraZenecaParexelCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedHealthy Male SubjectsChina
-
Shanghai Henlius BiotechCompletedHealthy Male SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
Clinical Trials on Exforge tab. 10/160mg
-
HK inno.N CorporationCompletedHealthy Male SubjectsKorea, Republic of
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male SubjectsKorea, Republic of
-
HK inno.N CorporationCompletedHypertension | HyperlipidemiasKorea, Republic of
-
Hanlim Pharm. Co., Ltd.Completed
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male SubjectsKorea, Republic of
-
HK inno.N CorporationCompleted
-
HK inno.N CorporationUnknown
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
HK inno.N CorporationCompleted